Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Northfelt, D. W.
Right arrow Articles by Henry, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Northfelt, D. W.
Right arrow Articles by Henry, D. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 2445-2451, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial

DW Northfelt, BJ Dezube, JA Thommes, BJ Miller, MA Fischl, A Friedman-Kien, LD Kaplan, C Du Mond, RD Mamelok and DH Henry
University of California, San Francisco, USA. dnorthfelt@pol.net

PURPOSE: Kaposi's sarcoma (KS), the most common neoplasm in patients with AIDS, is a significant clinical problem for which current therapies are frequently unsatisfactory. We conducted a randomized phase III clinical trial to compare the efficacy and toxicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combination chemotherapy in patients with advanced AIDS-related KS (AIDS-KS). PATIENTS AND METHODS: Two hundred fifty-eight patients with advanced AIDS-KS were randomly assigned to receive either pegylated- liposomal doxorubicin (20 mg/m2) or the combination of doxorubicin (20 mg/m2), bleomycin (10 mg/m2) and vincristine (1 mg) (ABV) every 14 days for six cycles. Standard response criteria, toxicity criteria, and predefined indicators of clinical benefit were examined to evaluate outcomes. RESULTS: Among 133 patients randomized to receive pegylated- liposomal doxorubicin, one achieved a complete clinical response and 60 achieved a partial response for an overall response rate of 45.9% (95% confidence interval [CI], 37% to 54%). Among 125 patients randomized to receive ABV, 31 achieved a partial response (24.8%; 95% confidence interval [CI], 17% to 32%). This difference was statistically significant (P < .001). In addition to objective responses, prospectively defined clinical benefits and toxicity outcomes also favored pegylated-liposomal doxorubicin. CONCLUSION: Pegylated- liposomal doxorubicin is more effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of AIDS-KS.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, and G. TING
Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/luc Xenografted Mouse Model
Anticancer Res, June 1, 2009; 29(6): 2111 - 2120.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat
AIDS-Related Malignancies: State of the Art and Therapeutic Challenges
J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Y. Zafar, D. N. Howell, and J. P. Gockerman
Malignancy After Solid Organ Transplantation: An Overview
Oncologist, July 1, 2008; 13(7): 769 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Lo, C.-T. Lin, and H.-C. Wu
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Mol. Cancer Ther., March 1, 2008; 7(3): 579 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, M. S. Webb, D. Waterhouse, and M. B. Bally
Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors
Clin. Cancer Res., February 15, 2008; 14(4): 1208 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
K. M. Skubitz and D. R. D'Adamo
Sarcoma
Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
R. Schlichemeyer, C. Chambers, and M. J. Gill
The oncology impact of highly active antiretroviral therapy
Journal of Oncology Pharmacy Practice, March 1, 2007; 13(1): 17 - 25.
[Abstract] [PDF]

Home page
 The OncologistHome page
T. Cooley, D. Henry, M. Tonda, S. Sun, M. O'Connell, and W. Rackoff
A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma
Oncologist, January 1, 2007; 12(1): 114 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura
Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors
Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 768 - 774.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Combs, N. Neil, and D. M. Aboulafia
Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study.
Oncologist, June 1, 2006; 11(6): 666 - 673.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. C. Cheung, L. Pantanowitz, and B. J. Dezube
AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy
Oncologist, June 1, 2005; 10(6): 412 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
G. Gambassi, R. Semeraro, V. Suma, A. Sebastio, and R. Antonelli Incalzi
Aggressive Behavior of Classical Kaposi's Sarcoma and Coexistence With Angiosarcoma
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2005; 60(4): 520 - 523.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al.
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations
Ann. Onc., November 1, 2003; 14(11): 1660 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
D. M. Aboulafia, D. Norris, D. Henry, R. J. Grossman, J. Thommes, D. Bundow, R. C. Yocum, and V. Stevens
9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial
Arch Dermatol, February 1, 2003; 139(2): 178 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
R. Sarid, A. Klepfish, and A. Schattner
Virology, Pathogenetic Mechanisms, and Associated Diseases of Kaposi Sarcoma-Associated Herpesvirus (Human Herpesvirus 8)
Mayo Clin. Proc., September 1, 2002; 77(9): 941 - 949.
[Abstract] [PDF]

Home page
 JCOHome page
S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn
Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study
J. Clin. Oncol., August 1, 2002; 20(15): 3236 - 3241.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. H. C. Bramwell, D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri
Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma
Clin. Cancer Res., February 1, 2002; 8(2): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Lyass, A. Hubert, and A. A. Gabizon
Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies
Clin. Cancer Res., October 1, 2001; 7(10): 3040 - 3046.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Holkova, K. Takeshita, D. M. Cheng, M. Volm, C. Wasserheit, R. Demopoulos, and A. Chanan-Khan
Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi's Sarcoma Treated With Chemotherapy
J. Clin. Oncol., September 15, 2001; 19(18): 3848 - 3851.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. J. Landau, B. J. Poiesz, S. Dube, J. A. Bogart, L. B. Weiner, and A.-K. Souid
Classic Kaposi's Sarcoma Associated with Human Herpesvirus 8 Infection in a 13-Year-Old Male: A Case Report
Clin. Cancer Res., August 1, 2001; 7(8): 2263 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, U. Malik, L. Rajdev, C. Sarta, U. Hopkins, and A. C. Wolff
Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
J. Clin. Oncol., June 15, 2001; 19(12): 3117 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Harrington, S. Mohammadtaghi, P. S. Uster, D. Glass, A. M. Peters, R. G. Vile, and J. S. W. Stewart
Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes
Clin. Cancer Res., February 1, 2001; 7(2): 243 - 254.
[Abstract] [Full Text]

Home page
 Arch DermatolHome page
B. J. Dezube
AIDS-Related Kaposi Sarcoma: The Role of Local Therapy for a Systemic Disease
Arch Dermatol, December 1, 2000; 136(12): 1554 - 1556.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Sgadari, E. Toschi, C. Palladino, G. Barillari, D. Carlei, A. Cereseto, C. Ciccolella, R. Yarchoan, P. Monini, M. Sturzl, et al.
Mechanism of Paclitaxel Activity in Kaposi's Sarcoma
J. Immunol., July 1, 2000; 165(1): 509 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, P. S. Uster, R. G. Vile, and J. S. W. Stewart
Pegylated Liposomes Have Potential as Vehicles for Intratumoral and Subcutaneous Drug Delivery
Clin. Cancer Res., June 1, 2000; 6(6): 2528 - 2537.
[Abstract] [Full Text]

Home page
 JCOHome page
G. Nasti, D. Errante, R. Talamini, G. Rizzardini, M. Fasan, G. Landonio, C. Zeroli, G. Chichino, E. Nigra, E. Vaccher, et al.
Vinorelbine Is an Effective and Safe Drug for AIDS-Related Kaposi’s Sarcoma: Results of a Phase II Study
J. Clin. Oncol., April 7, 2000; 18(7): 1550 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. Antman and Y. Chang
Kaposi's Sarcoma
N. Engl. J. Med., April 6, 2000; 342(14): 1027 - 1038.
[Full Text] [PDF]

Home page
 ChestHome page
D. M. Aboulafia
The Epidemiologic, Pathologic, and Clinical Features of AIDS-Associated Pulmonary Kaposi’s Sarcoma
Chest, April 1, 2000; 117(4): 1128 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. W. Cheung, S. C. Remick, N. Azarnia, J. A. Proper, J. R. Barrueco, and B. J. Dezube
AIDS-related Kaposi's Sarcoma: A Phase II Study of Liposomal Doxorubicin
Clin. Cancer Res., November 1, 1999; 5(11): 3432 - 3437.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. S. Gill, A. Tulpule, B. M. Espina, S. Cabriales, J. Bresnahan, M. Ilaw, S. Louie, N. F. Gustafson, M. A. Brown, C. Orcutt, et al.
Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma
J. Clin. Oncol., June 1, 1999; 17(6): 1876 - 1876.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online